Le Lézard
Classified in: Health
Subject: POL

OCHIN Deeply Disappointed Over Omission of 42 CFR Part 2 Reform in Opioid Package


PORTLAND, Ore., Sept. 27, 2018 /PRNewswire/ -- Earlier this week, U.S. Senate and House leaders agreed upon an amended opioid legislation package, the SUPPORT for Patients and Communities Act, H.R.6. While OCHIN supports this desperately needed legislation, we are deeply disappointed that a critical piece was omitted, The Overdose Prevention and Patient Safety (OPPS) Act, H.R. 6082. The OPPS Act would have aligned policy around substance use disorder records with HIPAA privacy regulations, ensuring all patients receive effective and coordinated care.

OCHIN (PRNewsfoto/OCHIN)

"Successful care coordination, especially in community health centers and the patients they support, cannot take place without removing unnecessary and obsolete restrictions around the sharing of patient records related to substance abuse. Without this modernization, the objectives set out in the opioid package cannot be fully achieved. Without reform, providers cannot access a full medical record and share critical information to treat the whole patient," says Abby Sears, the CEO of OCHIN.

As a member of the Partnership to Amend 42 CFR Part 2, OCHIN is aligned with over 170 patient, health care provider, physician, addiction treatment, municipal, and other organizations, as well as the nation's governors, state Medicaid directors, and the Department of Health and Human Services, who all voiced their support for this Part 2 reform. These national health care providers and partners are patently aware that this alignment is critical for safe, coordinated care delivery in the face of this devastating epidemic.

"Despite this setback, we are not giving up on Part 2 reform to reach our goal of a complete medical record, which is necessary to ensure the delivery of the highest level of care, regardless of location or provider," Sears went on to say.

OCHIN actively urges the Senate to hold a separate vote on the OPPS Act to ensure enhanced patient safety, care coordination, and consumer protections become law.  

About OCHIN

Portland, Oregon-based nonprofit OCHIN is one of the largest and most successful health information and innovation networks, serving over 500 organizations comprised of more than 10,000 clinicians across the nation with solutions that improve the integration and delivery of health care services. As a learning organization, OCHIN started with a commitment to deliver health information technology support and services and has continued to provide its expanding community of customers and partners with the innovative tools, knowledge, and voice needed to participate in the national health care landscape. Learn more at www.ochin.org.

Media Contact: Jennifer Stoll, 503.720.9882, [email protected]

 

SOURCE OCHIN


These press releases may also interest you

at 00:25
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial...

28 mar 2024
The report titled "Central Lab Market by Service Type (Anatomic Pathology/Histology, Biomarker Services, Genetic Services), Phase (Phase 1, Phase 2, Phase 3), Therapeutic Area, End-use - Global Forecast 2024-2030" is now available on...

28 mar 2024
The report titled "Personalized Nutrition Market by Measurement Type (Active Measurement, Standard Measurement), Application (Indication-based, Standard Supplements), Distribution Channel, End-Use - Global Forecast 2024-2030" is now available on...

28 mar 2024
The report titled "Carbon Dioxide Incubator Market by Product (Air Jacketed CO2 Incubators, Direct Heat CO2 Incubators, Water Jacketed CO2 Incubators), Capacity (100-200 Litre, Above 200 Litre, Below 100 Litre), Application, End User - Global...

28 mar 2024
The "Global Clinical In Vitro Diagnostic Medical Laboratory Services Market: Strategy & Trends with Volume & Price Forecasts by Chemistry, Hematology, Microbiology, Pathology, Covid-19, and Molecular Dx by Country. Updated with Impact of COVID-19"...

28 mar 2024
The "Molecular Diagnostics at the Point of Care. By Application, Technology, Place, Product and by Country. With Executive Guides and Customization 2023 - 2027 " report has been added to  ResearchAndMarkets.com's offering. Infectious disease Dx is...



News published on and distributed by: